Investing.com - Kintara Therapeutics reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Kintara Therapeutics announced earnings per share of $-0.0700 on revenue of $4.71M. Analysts polled by Investing.com anticipated EPS of $-0.1800 on revenue of $0.00.
Kintara Therapeutics shares are down 29.95% from the beginning of the year, still down 90.53% from its 52 week high of $0.96 set on November 10, 2021.
Kintara Therapeutics follows other major Healthcare sector earnings this month
Kintara Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar